FOXO1 and type 2 diabetes mellitus: Collectively, all these data indicate that GPS significantly inhibits gluconeogenesis by regulating the PI3K/AKT/FOXO1 signaling pathway in liver of the diabetic mice, indicating that this may be the potential mechanism by which GPS treatment improves symptoms of type 2 diabetes.